MapLight Therapeutics Reports Phase 2 Trial Results for Schizophrenia Drug

MapLight Therapeutics, Inc. has announced the topline results from its ZEPHYR Phase 2 trial of ML-007C-MA, a drug candidate for adults with schizophrenia experiencing acute psychosis. The company disclosed these findings in an 8-K filing and a press release, with a conference call planned for further discussion. These results are a critical step in the drug's development, potentially impacting future treatment options for schizophrenia.